47 results on '"Savio, V."'
Search Results
2. POS0974 CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY
- Author
-
Brigante, J. A., primary, Roberts, K., additional, Isnardi, C. A., additional, Gómez, G., additional, Holguín Arias, L. L., additional, Pons-Estel, B., additional, Gamba, J., additional, Haye, M., additional, Dapeña, J. M., additional, Secco, A., additional, Savio, V., additional, Soliz Cordero, C., additional, Gobbi, C., additional, Velozo, E., additional, Catay, E., additional, Aste, N., additional, Medina, G., additional, Exeni, I. E., additional, Gomez, G., additional, Pereira, D. A., additional, Granel, A. B., additional, Petkovic, I., additional, Pisoni, C., additional, Smichowski, A. M., additional, Sacnun, M., additional, Berbotto, G., additional, García, M., additional, Viola, M., additional, Bovea Castelblanco, G., additional, Saurit, V., additional, Kerzberg, E., additional, Larroude, M. S., additional, De La Sota, M. E., additional, Bertoli, A., additional, Diaz, M. P., additional, Castro, C., additional, Citera, G., additional, Casado, G., additional, Quintana, R., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. AB1666 CLUSTER ANALYSIS TO IDENTIFY PATIENT GROUPS AND ASSESS THE PRESENCE OF ADVERSE EVENTS. REAL WORLD EVIDENCE FROM THE BIOBADASAR 3.0 REGISTRY
- Author
-
Brigante, J. A., primary, Roberts, K., additional, Isnardi, C., additional, Gómez, G., additional, Haye, M., additional, García, M., additional, Gobbi, C., additional, Casado, G., additional, Holguín Arias, L. L., additional, Dapeña, J. M., additional, Papasidero, S., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I., additional, Bertoli, A., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Sacnun, M., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Kerzberg, E., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional
- Published
- 2023
- Full Text
- View/download PDF
4. AB1298 PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-CoV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY
- Author
-
Bravo, A., primary, Barbich, T., additional, Isnardi, C., additional, Citera, G., additional, Schneeberger, E. E., additional, Quintana, R., additional, Pisoni, C., additional, Pera, M., additional, Velozo, E., additional, Pereira, D. A., additional, Alba, P., additional, Albiero, J. A., additional, Villafañe, J., additional, Maldonado Ficco, H., additional, Savio, V., additional, Aguero, S. E., additional, Rojas Tessel, R., additional, Quaglia, M. I., additional, Gálvez Elkin, M. S., additional, Pendon, G. P., additional, Aeschlimann, C., additional, Rodriguez Gil, G. F., additional, Viola, M., additional, Romeo, C., additional, Maldini, C., additional, Conti, S. M., additional, Gallo, R., additional, Ibañez Zurlo, L., additional, Tamborenea, M. N., additional, Pineda Vidal, S. I., additional, Guaglianone, D., additional, Mareco, J. M., additional, Goizueta, C., additional, Novatti, E., additional, Guzzanti, F., additional, Gómez, G., additional, Roberts, K., additional, and Pons-Estel, G., additional
- Published
- 2023
- Full Text
- View/download PDF
5. POS0660 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES. 10 YEARS OF REAL-LIFE DATA. BIOABASAR 3.0 REGISTRY
- Author
-
Brigante, A., primary, Isnardi, C. A., additional, Quintana, R., additional, Gómez, G., additional, Roberts, K., additional, Haye, M., additional, Costi, A. C., additional, Perez, N., additional, Astesana, P., additional, Smichowski, A. M., additional, Sorrentino, L., additional, Alcivar Navarrete, J., additional, Raggio, J. C., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I. E., additional, Kirmayr, K. I., additional, Catay, E., additional, D’Angelo, M. E., additional, Pons-Estel, B., additional, Paira, S., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Callahuara, N., additional, Medina, G., additional, Pisoni, C., additional, Alvarez, A., additional, Fernandez, L., additional, Sacnun, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Aste, N., additional, Kerzberg, E., additional, Gallardo, M. D. L. Á., additional, Savio, V., additional, Gamba, J., additional, Citera, G., additional, Soriano, E., additional, Casado, G., additional, Graf, C., additional, Pons-Estel, G., additional, and Delavega, M., additional
- Published
- 2022
- Full Text
- View/download PDF
6. POS0655 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES AS REGARDS TO AGE GROUPS. BIOBADASAR 3.0 REGISTRY.
- Author
-
Brigante, A., primary, Isnardi, C. A., additional, Gómez, G., additional, Quintana, R., additional, Haye, M., additional, Roberts, K., additional, García, M., additional, Gomez, G., additional, Gobbi, C., additional, Casado, G., additional, Rebak, J., additional, Dapeña, J. M., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I. E., additional, Bertoli, A., additional, Giorgis, P., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Paira, S., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Alvarez, A., additional, Aguero, S. E., additional, Fernandez, L., additional, Sacnun, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Lazaro, A., additional, Kerzberg, E., additional, Gallardo, M. D. L. Á., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and Delavega, M., additional
- Published
- 2022
- Full Text
- View/download PDF
7. POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID -19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID
- Author
-
Savio, V., primary, Maldini, C., additional, Alba, P., additional, Saurit, V., additional, Berbotto, G., additional, Pisoni, C., additional, Tissera, Y., additional, Nieto, R., additional, Maldonado, F., additional, Ornella, S., additional, Gobbi, C., additional, Baños, A. R., additional, Vivero, F., additional, Exeni, I. E., additional, Cusa, A., additional, Bellomio, V. I., additional, Perez Alamino, R., additional, Gomez, G., additional, Zelaya, D., additional, Risueño, F., additional, Quaglia, M. I., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, Delavega, M., additional, Lazaro, M. A., additional, Mercé, A. L., additional, Finucci, P., additional, Matellan, C. E., additional, Romeo, C., additional, Martire, V., additional, Moyano, S., additional, Martin, M. L., additional, Picco, E., additional, Goizueta, C., additional, Tralice, E. R., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Gallo, R., additional, Pineda Vidal, S. I., additional, Velasco Zamora, J. L., additional, Lloves Schenone, N., additional, Cosentino, V., additional, Rodriguez, F., additional, Diaz, M. P., additional, Viola, M., additional, Mamani Ortega, M. L., additional, Buschiazzo, E., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, and Pons-Estel, G., additional
- Published
- 2022
- Full Text
- View/download PDF
8. POS1200 DIFFERENCES BETWEEN THE FIRST AND THE SECOND WAVE OF SARS-COV-2 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES IN ARGENTINA: DATA FROM THE SAR-COVID REGISTRY
- Author
-
Bertoli, A., primary, Muñoz, L., additional, López Pérez, M. J., additional, Sanchez Freytes, L., additional, Castaño, M. S., additional, Saurit, V., additional, Berbotto, G., additional, Alle, G., additional, Severina, M., additional, Nieto, R., additional, Maldonado, F., additional, Pera, M., additional, Cogo, A. K., additional, Baños, A. R., additional, Vivero, F., additional, Pereira, D. A., additional, Cosatti, M., additional, Savio, V., additional, Perez Alamino, R., additional, Medina, M. A., additional, Schmid, M., additional, Risueño, F., additional, Quaglia, M. I., additional, Pendon, G. P., additional, Casalla, L., additional, Delavega, M., additional, Lazaro, M. A., additional, Finucci, P., additional, Morbiducci, J., additional, Romeo, C., additional, Cucchiaro, N., additional, Moyano, S., additional, Barbich, T., additional, Conti, S. M., additional, Goizueta, C., additional, Tralice, E. R., additional, Maldini, C., additional, Rebak, J., additional, Gallo, R., additional, Maid, P., additional, Velasco Zamora, J. L., additional, Lloves Schenone, N., additional, Porta, S., additional, Morales, N. S., additional, Diaz, M. P., additional, Viola, M., additional, Buschiazzo, E., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, Pons-Estel, G., additional, and Matellan, C. E., additional
- Published
- 2022
- Full Text
- View/download PDF
9. AB1094 SAFETY AND EFFICACY OF VACCINES FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: DATA FROM THE ARGENTINEAN REGISTRY SAR-CoVAC
- Author
-
Isnardi, C. A., primary, Roberts, K., additional, Quintana, R., additional, Kreimer, J., additional, Echeverria, C., additional, Luna, P. C., additional, Virasoro, B. M., additional, Exeni, I. E., additional, Kogan, N., additional, Correa, M. D. L. A., additional, Pereira, D. A., additional, Zelaya, D., additional, Tissera, Y., additional, Pisoni, C., additional, Gálvez Elkin, M. S., additional, Alonso, C. G., additional, Cogo, A. K., additional, Cosatti, M., additional, Garcia, L., additional, Retamozo, C., additional, Severina, M., additional, Nieto, R., additional, Rosemffet, M., additional, Mussano, E. D., additional, Bertoli, A., additional, Delavega, M., additional, Savio, V., additional, Cosentino, V., additional, Roldan, B., additional, Maldonado Ficco, H., additional, Maid, P., additional, Calle Montoro, C., additional, Fernandez, L., additional, Leguizamón, M. L., additional, Gómez Vara, A. B., additional, Alfaro, M. A., additional, Landi, M., additional, Herscovich, N., additional, Maldini, C., additional, De la Vega Fernandez, S. S., additional, Velozo, E., additional, Giorgis, P., additional, Sattler, M. E., additional, Reyes Gómez, C., additional, Perrotat, L., additional, Reimundes, C., additional, Ezquer, R. A., additional, Saurit, V., additional, Flores Trejo, J., additional, Cerda, O. L., additional, Crespo Rocha, M. G., additional, Carrizo Abarza, V., additional, Strusberg, I., additional, Rojas Tessel, R., additional, Verna, G., additional, Bande, J. M., additional, Farfan, P., additional, Berbotto, G., additional, Pons-Estel, G., additional, and Schneeberger, E. E., additional
- Published
- 2022
- Full Text
- View/download PDF
10. POS1204 SARS-CoV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA
- Author
-
Cosatti, M., primary, D´ Angelo, M. E., additional, Petkovic, I. E., additional, Correa, M. D. L. A., additional, Zelaya, D., additional, Gálvez Elkin, M. S., additional, Cogo, A. K., additional, Retamozo, C., additional, Nieto, R., additional, Mussano, E. D., additional, Cavillon, E. M., additional, Savio, V., additional, Roldan, B., additional, Maid, P., additional, Fernandez, L., additional, Muñoz, L., additional, Leguizamón, M. L., additional, Herscovich, N., additional, Alfaro, M. A., additional, Maldini, C., additional, Giorgis, P., additional, Reyes Gómez, C., additional, Reimundes, C., additional, Saurit, V., additional, Cerda, O. L., additional, Crespo Rocha, M. G., additional, Strusberg, I., additional, Verna, G., additional, Quaglia, M. I., additional, Picco, E., additional, Catalan Pellet, S., additional, Galan, M., additional, Troyano, Z., additional, Perandones, M., additional, Kreimer, J., additional, Luna, P. C., additional, Echeverria, C., additional, Virasoro, B. M., additional, Roberts, K., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Pons-Estel, G., additional, and Pisoni, C., additional
- Published
- 2022
- Full Text
- View/download PDF
11. POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID.
- Author
-
Gómez Vara, A. B., primary, Barbich, T., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Citera, G., additional, Castro Coello, V. V., additional, Baez, R., additional, Haye, M., additional, Reyes, A. A., additional, Albiero, J. A., additional, Tanten, R., additional, Velozo, E., additional, Alba, P., additional, Gamba, M. J., additional, Alonso, C. G., additional, Maldonado Ficco, H., additional, Gallino Yanzi, J., additional, Savio, V., additional, Asnal, C., additional, Matellan, C., additional, Takashima, L., additional, Carlevaris, L., additional, Gálvez Elkin, M. S., additional, Scafati, J., additional, García, M., additional, German, N., additional, Werner, M. L., additional, Aeschlimann, C., additional, Aguero, S. E., additional, Calvo, M. E., additional, Gonzalez Lucero, L., additional, Rodriguez Gil, G. F., additional, Mauri, M., additional, Petruzzelli, S., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Alonso, D., additional, Tomas, J. L., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Mareco, J. M., additional, Guaglianone, D., additional, Ledesma, C., additional, Diaz, M. P., additional, Bedoya, M. E., additional, Kisluk, B., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, and Pons-Estel, G., additional
- Published
- 2022
- Full Text
- View/download PDF
12. PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-COV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY.
- Author
-
Bravo, A., Barbich, T., Isnardi, C., Citera, G., Schneeberger, E. E., Quintana, R., Pisoni, C., Pera, M., Velozo, E., Pereira, D. A., Alba, P., Albiero, J. A., Villafañe, J., Ficco, H. Maldonado, Savio, V., Aguero, S. E., Tessel, R. Rojas, Quaglia, M. I., Elkin, M. S. Gálvez, and Pendon, G. P.
- Published
- 2023
- Full Text
- View/download PDF
13. AB0342 OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?
- Author
-
Serrano Morales, R., primary, Nieto, R., additional, Porta, S., additional, Roberts, K., additional, Lema, L., additional, Maldini, C., additional, Tissera, Y., additional, Albiero, J. A., additional, Savio, V., additional, Goizueta, C., additional, Lobo, V., additional, Broll, A., additional, Cucchiaro, N., additional, ¨perez, S., additional, Izaguirre, P., additional, Estevez, A., additional, Abalo, A. I., additional, Etcheverry, M., additional, Bellomio, V. I., additional, Leguizamón, M. L., additional, Antoniol, N., additional, Perandones, C., additional, Pisoni, C., additional, De la Torre, M. L., additional, García, M., additional, Velloso, M. S., additional, Sacnun, M., additional, Gobbi, C., additional, Guaglione, D., additional, Vivero, F., additional, Saurit, V., additional, Benzaquen, N., additional, Nemman, V., additional, Remondino, G., additional, Machado Escobar, M., additional, Scolnik, M., additional, Danielsen, C., additional, Gomez, G., additional, Babini, A. M., additional, Brigante, A., additional, Luissi, A., additional, Castro Coello, V. V., additional, Sorrentino, L., additional, Berman, H., additional, Alba, P., additional, and Pons-Estel, G., additional
- Published
- 2021
- Full Text
- View/download PDF
14. AB0338 PREGNANCY OUTCOMES IN ADOLESCENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
- Author
-
Alba, P., primary, Tissera, Y., additional, Cucchiaro, N., additional, Savio, V., additional, Serrano Morales, R., additional, Quaglia, M. I., additional, Albiero, J. A., additional, Juarez, V., additional, Gobbi, C. A., additional, Yorio, M., additional, and Crespo Espindola, M. E., additional
- Published
- 2021
- Full Text
- View/download PDF
15. POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE)
- Author
-
Reyes, A. A., primary, Alle, G., additional, Tanten, R., additional, Scolnik, M., additional, Soriano, E., additional, Berbotto, G., additional, Haye, M., additional, Gamba, M. J., additional, Nieto, R., additional, García, M., additional, Savio, V., additional, Gonzalez Lucero, L., additional, Alba, P., additional, Takashima, L., additional, Risueño, F., additional, Casalla, L., additional, Cucchiaro, N., additional, Bertoli, A., additional, Porta, S., additional, Maldini, C., additional, Gallo, R., additional, Goizueta, C., additional, Picco, E., additional, Quintana, R., additional, Roberts, K., additional, Isnardi, C. A., additional, and Pons-Estel, G., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Levels of type I interferon in patients with systemic lupus erythematosus
- Author
-
Erramuspe, C., primary, Racca, M., additional, Siemsen, M., additional, Pelosso, M., additional, Quaglia, M., additional, Tissera, Y., additional, Alonso, C., additional, Savio, V., additional, Albiero, J., additional, Gobbi, C., additional, Alba, P., additional, Boffelli, L., additional, Maccioni, M., additional, and Demarchi, M., additional
- Published
- 2021
- Full Text
- View/download PDF
17. AB0830 LIPID PROFILE IN PSORIATIC ARTHRITIS. FREQUENCY AND ASSOCIATION WITH DISEASE ACTIVITY.
- Author
-
Savio, V., primary, Tissera, Y., additional, Quaglia, M. I., additional, Albiero, J. A., additional, Alonso, C. G., additional, Demarchi, M., additional, Maldini, C., additional, Gobbi, C., additional, Yorio, M., additional, Martini, A. C., additional, Castrillon, M. E., additional, and Alba, P., additional
- Published
- 2020
- Full Text
- View/download PDF
18. Chronic inflammatory demyelinating polyneuropathy as a presentation of systemic lupus erythematosus
- Author
-
Alonso, C., primary, Gobbi, C., additional, Quaglia, M. I., additional, Tissera, Y., additional, Savio, V., additional, Albiero, A., additional, and Alba, P., additional
- Published
- 2020
- Full Text
- View/download PDF
19. CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY.
- Author
-
Brigante, J. A., Roberts, K., Isnardi, C. A., Gómez, G., Holguín Arias, L. L., Pons-Estel, B., Gamba, J., Haye, M., Dapeña, J. M., Secco, A., Savio, V., Soliz Cordero, C., Gobbi, C., Velozo, E., Catay, E., Aste, N., Medina, G., Exeni, I. E., Gomez, G., and Pereira, D. A.
- Published
- 2023
- Full Text
- View/download PDF
20. Evaluation of scale-adaptive simulation for transonic cavity flows
- Author
-
Savio V. Babu, George Zografakis, George N. Barakos, and Alexander Kusyumov
- Subjects
Modeling and Simulation ,General Engineering - Abstract
Scale-adaptive simulations of transonic cavities with and without doors are presented in this paper. Results were compared with detached-eddy simulations for cavities with length-to-depth ratios of 5 and 7. The Mach and Reynolds numbers (based on the cavity length) were 0.85 and 6.5 × 106, respectively, and the grid sizes were 5.0 million for the clean cavity with doors-off and 5.5 million for the clean cavity with doors-on. Instantaneous Mach number contours showed that the shear layer broke down for both the doors on and doors off cases and that the flows had a high level of unsteadiness inside them. The two L/D ratios of cavities were seen to have similar acoustic signatures reaching maximum sound levels of 170 dB. Spectral analyses for the cavities without doors revealed that by changing the length-to-depth ratio from five to seven, the dominant acoustic modes at the front and rear of the cavities were shifted from the second and third modes to the first and second modes respectively. Proper orthogonal decomposition was used to reduce the data storage using modes constructed from flowfield snapshots taken at regular intervals.
- Published
- 2016
21. Porous silicon passivation for applications in sensors and photovoltaics: Optical characterization
- Author
-
Toledo, Rosimara P., primary, Dias, Carlos E. S., additional, Huanca, Danilo R., additional, Zaccaro, Savio V., additional, and Salcedo, Walter J., additional
- Published
- 2016
- Full Text
- View/download PDF
22. Evaluation of scale-adaptive simulation for transonic cavity flows
- Author
-
Babu, Savio V., primary, Zografakis, George, additional, Barakos, George N., additional, and Kusyumov, Alexander, additional
- Published
- 2016
- Full Text
- View/download PDF
23. AB1097 The Impact of Systemic Lupus Erythematosus on Work Productivity: Data from Patients from the Province of Cordoba, Argentina
- Author
-
Bertoli, A., primary, Lόpez Pérez, M.J., additional, Alba, P., additional, Albiero, A., additional, Albiero, E., additional, Alessio, D., additional, Albarelos, A., additional, Asbert, P., additional, Astesana, P., additional, Audisio, M., additional, Benzaquén, N., additional, Castaños Menescardi, M.S., additional, Colazo, M., additional, Encinas, L., additional, Haye Salinas, M.J., additional, Maldini, C., additional, Maldoado, A., additional, Morales, M.J., additional, Onetti, L., additional, Saurit, V., additional, Savio, V., additional, Werner, M., additional, and Gobbi, C., additional
- Published
- 2015
- Full Text
- View/download PDF
24. AB1103 Cumulative Rate and Factors Associated with Self-Reported Work Disability Among Patients with Systemic Lupus Erythematosus: Data from the Province of Cordoba, Argentina
- Author
-
Lόpez Pérez, M.J., primary, Bertoli, A., additional, Alba, P., additional, Albiero, A., additional, Albiero, E., additional, Alessio, D., additional, Albarelos, A., additional, Asbert, P., additional, Astesana, P., additional, Audisio, M., additional, Benzaquén, N., additional, Castaños Menescardi, M.S., additional, Colazo, M., additional, Encinas, L., additional, Haye Salinas, M.J., additional, Maldini, C., additional, Maldoado, A., additional, Morales, M.J., additional, Onetti, L., additional, Saurit, V., additional, Savio, V., additional, Werner, M., additional, and Gobbi, C., additional
- Published
- 2015
- Full Text
- View/download PDF
25. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
- Author
-
Zara Izadi, Milena A Gianfrancesco, Gabriela Schmajuk, Lindsay Jacobsohn, Patricia Katz, Stephanie Rush, Clairissa Ja, Tiffany Taylor, Kie Shidara, Maria I Danila, Katherine D Wysham, Anja Strangfeld, Elsa F Mateus, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Samar Al-Emadi, Jeffrey A Sparks, Tiffany Y-T Hsu, Naomi J Patel, Leanna Wise, Emily Gilbert, Alí Duarte-García, Maria O Valenzuela-Almada, Manuel F Ugarte-Gil, Lotta Ljung, Carlo A Scirè, Greta Carrara, Eric Hachulla, Christophe Richez, Patrice Cacoub, Thierry Thomas, Maria J Santos, Miguel Bernardes, Rebecca Hasseli, Anne Regierer, Hendrik Schulze-Koops, Ulf Müller-Ladner, Guillermo Pons-Estel, Romina Tanten, Romina E Nieto, Cecilia N Pisoni, Yohana S Tissera, Ricardo Xavier, Claudia D Lopes Marques, Gecilmara C S Pileggi, Philip C Robinson, Pedro M Machado, Emily Sirotich, Jean W Liew, Jonathan S Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Monique Gore-Massy, Zachary S Wallace, Jinoos Yazdany, Brahim Dahou, Gimena Gómez, Karen Roberts, Roberto M Baez, Vanessa V Castro Coello, María J Haye Salinas, Federico N Maldonado, Alvaro A Reyes, Gelsomina Alle, Hernán Maldonado Ficco, Romina Nieto, Carla Gobbi, Yohana Tissera, Cecilia Pisoni, Alba Paula, Juan A Albiero, Maria M Schmid, Micaela Cosatti, Maria J Gamba, Carlevaris Leandro, María A Cusa, Noelia German, Veronica Bellomio, Lorena Takashima, Mariana Pera, Karina Cogo, Maria S Gálvez Elkin, María A Medina, Veronica Savio, Romina Rojas Tessel, Rodolfo P Alamino, Marina L Werner, Sofía Ornella, Luciana Casalla, Maria de la Vega, María Severina, Mercedes García, Luciana Gonzalez Lucero, Cecilia Romeo, Sebastián Moyano, Tatiana Barbich, Ana Bertoli, Andrea Baños, Sandra Petruzzelli, Carla Matellan, Silvana Conti, Maria A Lazaro, Gustavo F Rodriguez Gil, Fabian Risueño, Maria I Quaglia, Julia Scafati, Natalia L Cuchiaro, Jonathan E Rebak, Susana I Pineda, María E Calvo, Eugenia Picco, Josefina G Yanzi, Pablo Maid, Debora Guaglianone, Julieta S Morbiducci, Sabrina Porta, Natalia Herscovich, José L Velasco Zamora, Boris Kisluk, Maria S Castaños Menescardi, Rosana Gallo, María V Martire, Carla Maldini, Cecilia Goizueta, Sabrina S de la Vega Fernandez, Carolina Aeschlimann, Gisela Subils, Eva Rath, Yves Piette, Mieke Devinck, Bea Maeyaert, Francinne Machado Ribeiro, Sandra L Euzebio Ribeiro, Marcelo Pinheiro, Sebastián Ibáñez, Anne-Marie Chassin Trubert, Lingli Dong, Lui Cajas, Marko Barešić, Branimir Anić, Melanie-Ivana Ćulo, Tea A Pavelić, Kristina K Stranski, Boris Karanovic, Jiri Vencovsky, Marta Píchová, Maria Filkova, Hesham Hamoud, Dimitrios Vassilopoulos, Gabriela M Guzman Melgar, Ho So, Márta Király, Mahdi Vojdanian, Alexandra Balbir Gurman, Fatemah Abutiban, Julija Zepa, Inita Bulina, Loreta Bukauskiene, Beatriz E Zazueta Montiel, Angel A Castillo Ortiz, Erick Zamora Tehozol, David Vega Morales, Diana Cervántes Rosete, Eduardo Martín Nares, Tatiana S Rodriguez Reyna, Marina Rull Gabayet, Deshiré Alpízar Rodríguez, Fedra Irazoque, Xochitl Jimenez, Lenny Geurts van Bon, Theo Zijlstra, Monique Hoekstra, Nasra Al Adhoubi, Babur Salim, Enrique Giraldo, Ariel Salinas, Manuel Ugarte Gil, Jarosław Nowakowski, Richard Conway, Rachael Flood, Geraldine McCarthy, Ioana Felea, Ileana Filipescu, Simona Rednic, Laura Groseanu, Maria M Tamas, Vanda Mlynarikova, Martina Skamlova, Martin Zlnay, Dagmar Mičeková, Lubica Capova, Zelmira Macejova, Emőke Šteňová, Helena Raffayova, Gabriela Belakova, Eva Strakova, Marieta Senčarová, Soňa Žlnayová, Anna Sabová, Daniela Spisakova, Mária Oetterová, Olga Lukacova, Martina Bakosova, Alojzija Hocevar, Natalia de la Torre Rubio, Juan J Alegre Sancho, Montserrat Corteguera Coro, Juan C Cobeta Garcia, Maria C Torres Martin, Jose Campos, Jose A Gomez Puerta, Gozd K Yardimci, Servet Akar, Ozan C Icacan, Selda ÇELİK, Viktoriia Vasylets, Su-Ann Yeoh, Claire Vandevelde, Sasha Dunt, Jane Leeder, Elizabeth Macphie, Rosaria Salerno, Christine Graver, Katie Williams, Sheila O'Reilly, Kirsty Devine, Jennifer Tyler, Elizabeth Warner, James Pilcher, Samir Patel, Elena Nikiphorou, Laura Chadwick, Caroline M Jones, Beverley Harrison, Lucy Thornton, Diana O'Kane, Lucia Fusi, Audrey Low, Sarah Horton, Shraddha Jatwani, Sara Baig, Hammad Bajwa, Vernon Berglund, Angela Dahle, Walter Dorman, Jody Hargrove, Maren Hilton, Nicholas Lebedoff, Susan Leonard, Jennifer Morgan, Emily Pfeifer, Archibald Skemp, Jeffrey Wilson, Anne Wolff, Eduardo Cepeda, Derrick Todd, Denise Hare, Cassandra Calabrese, Christopher Adams, Arezou Khosroshahi, Adam Kilian, Douglas White, Melanie Winter, Theodore Fields, Caroline Siegel, Nicole Daver, Melissa Harvey, Neil Kramer, Concetta Lamore, Suneya Hogarty, Karen Yeter, Faizah Siddique, Byung Ban, Tamar Tanner, Eric Ruderman, William Davis, Robert Quinet, Evangeline Scopelitis, Karen Toribio, Tameka Webb Detiege, Jerald Zakem, Khurram Abbass, Gilbert Kepecs, Lilliam Miranda, Michael Guma, Ammar Haikal, Sushama Mody, Daric Mueller, Arundathi Jayatilleke, JoAnn Zell, Alison Bays, Kathryn Dao, Fatemeh Ezzati, Deborah Parks, David Karp, Guillermo Quiceno, Izadi, Z, Gianfrancesco, M, Schmajuk, G, Jacobsohn, L, Katz, P, Rush, S, Ja, C, Taylor, T, Shidara, K, Danila, M, Wysham, K, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Al-Emadi, S, Sparks, J, Hsu, T, Patel, N, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Ugarte-Gil, M, Ljung, L, Scire, C, Carrara, G, Hachulla, E, Richez, C, Cacoub, P, Thomas, T, Santos, M, Bernardes, M, Hasseli, R, Regierer, A, Schulze-Koops, H, Muller-Ladner, U, Pons-Estel, G, Tanten, R, Nieto, R, Pisoni, C, Tissera, Y, Xavier, R, Lopes Marques, C, Pileggi, G, Robinson, P, Machado, P, Sirotich, E, Liew, J, Hausmann, J, Sufka, P, Grainger, R, Bhana, S, Gore-Massy, M, Wallace, Z, Yazdany, J, Dahou, B, Gomez, G, Roberts, K, Baez, R, Castro Coello, V, Haye Salinas, M, Maldonado, F, Reyes, A, Alle, G, Maldonado Ficco, H, Gobbi, C, Paula, A, Albiero, J, Schmid, M, Cosatti, M, Gamba, M, Leandro, C, Cusa, M, German, N, Bellomio, V, Takashima, L, Pera, M, Cogo, K, Galvez Elkin, M, Medina, M, Savio, V, Rojas Tessel, R, Alamino, R, Werner, M, Ornella, S, Casalla, L, de la Vega, M, Severina, M, Garcia, M, Gonzalez Lucero, L, Romeo, C, Moyano, S, Barbich, T, Bertoli, A, Banos, A, Petruzzelli, S, Matellan, C, Conti, S, Lazaro, M, Rodriguez Gil, G, Risueno, F, Quaglia, M, Scafati, J, Cuchiaro, N, Rebak, J, Pineda, S, Calvo, M, Picco, E, Yanzi, J, Maid, P, Guaglianone, D, Morbiducci, J, Porta, S, Herscovich, N, Velasco Zamora, J, Kisluk, B, Castanos Menescardi, M, Gallo, R, Martire, M, Maldini, C, Goizueta, C, de la Vega Fernandez, S, Aeschlimann, C, Subils, G, Rath, E, Piette, Y, Devinck, M, Maeyaert, B, Machado Ribeiro, F, Euzebio Ribeiro, S, Pinheiro, M, Ibanez, S, Chassin Trubert, A, Dong, L, Cajas, L, Baresic, M, Anic, B, Culo, M, Pavelic, T, Stranski, K, Karanovic, B, Vencovsky, J, Pichova, M, Filkova, M, Hamoud, H, Vassilopoulos, D, Guzman Melgar, G, So, H, Kiraly, M, Vojdanian, M, Balbir Gurman, A, Abutiban, F, Zepa, J, Bulina, I, Bukauskiene, L, Zazueta Montiel, B, Castillo Ortiz, A, Zamora Tehozol, E, Vega Morales, D, Cervantes Rosete, D, Martin Nares, E, Rodriguez Reyna, T, Rull Gabayet, M, Alpizar Rodriguez, D, Irazoque, F, Jimenez, X, Geurts van Bon, L, Zijlstra, T, Hoekstra, M, Al Adhoubi, N, Salim, B, Giraldo, E, Salinas, A, Ugarte Gil, M, Nowakowski, J, Conway, R, Flood, R, Mccarthy, G, Felea, I, Filipescu, I, Rednic, S, Groseanu, L, Tamas, M, Mlynarikova, V, Skamlova, M, Zlnay, M, Micekova, D, Capova, L, Macejova, Z, Stenova, E, Raffayova, H, Belakova, G, Strakova, E, Sencarova, M, Zlnayova, S, Sabova, A, Spisakova, D, Oetterova, M, Lukacova, O, Bakosova, M, Hocevar, A, de la Torre Rubio, N, Alegre Sancho, J, Corteguera Coro, M, Cobeta Garcia, J, Torres Martin, M, Campos, J, Gomez Puerta, J, Yardimci, G, Akar, S, Icacan, O, Celik, S, Vasylets, V, Yeoh, S, Vandevelde, C, Dunt, S, Leeder, J, Macphie, E, Salerno, R, Graver, C, Williams, K, O'Reilly, S, Devine, K, Tyler, J, Warner, E, Pilcher, J, Patel, S, Nikiphorou, E, Chadwick, L, Jones, C, Harrison, B, Thornton, L, O'Kane, D, Fusi, L, Low, A, Horton, S, Jatwani, S, Baig, S, Bajwa, H, Berglund, V, Dahle, A, Dorman, W, Hargrove, J, Hilton, M, Lebedoff, N, Leonard, S, Morgan, J, Pfeifer, E, Skemp, A, Wilson, J, Wolff, A, Cepeda, E, Todd, D, Hare, D, Calabrese, C, Adams, C, Khosroshahi, A, Kilian, A, White, D, Winter, M, Fields, T, Siegel, C, Daver, N, Harvey, M, Kramer, N, Lamore, C, Hogarty, S, Yeter, K, Siddique, F, Ban, B, Tanner, T, Ruderman, E, Davis, W, Quinet, R, Scopelitis, E, Toribio, K, Webb Detiege, T, Zakem, J, Abbass, K, Kepecs, G, Miranda, L, Guma, M, Haikal, A, Mody, S, Mueller, D, Jayatilleke, A, Zell, J, Bays, A, Dao, K, Ezzati, F, Parks, D, Karp, D, Quiceno, G, and Repositório da Universidade de Lisboa
- Subjects
health care disparity ,Immunology ,air pollution ,cohort analysi ,mortality rate ,Autoimmune Disease ,Article ,coronavirus disease 2019 ,biocontainment ,Rheumatology ,male ,cardiovascular disease ,environmental factor ,death ,geographic distribution ,Immunology and Allergy ,follow up ,controlled study ,human ,population density ,outcome assessment ,rheumatic disease ,diabetes mellitu ,adult ,Prevention ,market ,temperature ,mortality ,United Kingdom ,Europe ,aged ,female ,workplace ,Good Health and Well Being ,human development ,particulate matter 2.5 ,statistical analysi ,North America ,incidence ,life expectancy ,social aspect ,COVID-19 Global Rheumatology Alliance Registry ,observational study ,demographic - Abstract
Published by Elsevier Ltd., Background: Differences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally. Methods: In this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death. Findings: 14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01-1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10-1·30]; p, MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]). KDW is supported by the Department of Veterans Affairs and the Rheumatology Research Foundation Scientist Development award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258). AD-G is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation. RH was supported by the Justus-Liebig University Giessen Clinician Scientist Program in Biomedical Research to work on this registry. JY is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155).
- Published
- 2022
26. Antimicrobial peptide human β-defensin-2 improves in vitro cellular viability and reduces pro-inflammatory effects induced by enteroinvasive Escherichia coli in Caco-2 cells by inhibiting invasion and virulence factors' expression
- Author
-
Alessandra, Fusco, Vittoria, Savio, Brunella, Perfetto, Roberto, Mattina, Giovanna, Donnarumma, Fusco, A., Savio, V., Perfetto, B., Mattina, R., and Donnarumma, G.
- Subjects
Diarrhea ,Caco-2 Cell ,beta-Defensins ,Virulence Factors ,Antimicrobial Peptide ,HBD-2 ,AMPs ,EIEC ,intestinal epithelium ,microbiota ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,beta-Defensin ,Virulence Factor ,Escherichia coli ,Humans ,Caco-2 Cells ,Child ,Antimicrobial Peptides ,AMP ,Human - Abstract
iEscherichia coli/iis one of the commensal species most represented in the intestinal microbiota. However, there are some strains that can acquire new virulence factors that enable them to adapt to new intestinal niches. These include enteroinvasiveiE. coli/i(EIEC) that is responsible for the bacillary dysentery that causes severe diarrheal symptoms in both children and adults. Due to the increasing onset of antibiotic resistance phenomena, scientific research is focused on the study of other therapeutic approaches for the treatment of bacterial infections. A promising alternative could be represented by antimicrobial peptides (AMPs), that have received widespread attention due to their broad antimicrobial spectrum and low incidence of bacterial resistance. AMPs modulate the immune defenses of the host and regulate the composition of microbiota and the renewal of the intestinal epithelium. With the aim to investigate an alternative therapeutic approach, especially in the case of antibiotic resistance, in this work we created a line of intestinal epithelial cells able to express high concentrations of AMP human β-defensin-2 (HBD-2) in order to test its ability to interfere with the pathogenicity mechanisms of EIEC. The results showed that HBD-2 is able to significantly reduce the expression of the proinflammatory cytokines by intestinal epithelial cells, the invasiveness ability of EIEC and the expression of invasion-associated genes.
- Published
- 2022
27. An Unconventional Oral Candidiasis in an Immunocompetent Patient
- Author
-
Alessandra Fusco, Maria Contaldo, Vittoria Savio, Adone Baroni, Giuseppe A. Ferraro, Dario Di Stasio, Alberta Lucchese, Adriana Chiaromonte, Giovanna Donnarumma, Rosario Serpico, Fusco, A., Contaldo, M., Savio, V., Baroni, A., Ferraro, G. A., Di Stasio, D., Lucchese, A., Chiaromonte, A., Donnarumma, G., and Serpico, R.
- Subjects
Microbiology (medical) ,yeast cell ,antimycogram ,Candidaspp ,hyphae ,Plant Science ,biofilm ,Ecology, Evolution, Behavior and Systematics ,oral candidiasi - Abstract
Oral candidiasis (OC) is an opportunistic fungal infection of the oral mucosae, sustained by Candida albicans or other non-albican Candida species (NAC), usually eradicated by conventional antifungals of the classes of azoles, polyenes, or derivative from echinocandins. OC usually occurs under predisposing local or systemic factors. C. lusitaniae is an opportunistic strain that is rarely responsible for human infection and occurs mainly in severe immunocompromised states. The present work reported an unconventional case of OC in an otherwise healthy immunocompetent woman sustained by C. lusitaniae and a multi-resistant strain of C. albicans.
- Published
- 2023
28. Antimicrobial Peptides Human Beta-Defensin-2 and -3 Protect the Gut During Candida albicans Infections Enhancing the Intestinal Barrier Integrity: In Vitro Study
- Author
-
Vittoria Savio, Giovanna Donnarumma, Maria Donniacuo, Alessandra Fusco, Brunella Perfetto, Fusco, A., Savio, V., Donniacuo, M., Perfetto, B., and Donnarumma, G.
- Subjects
0301 basic medicine ,Pore Forming Cytotoxic Proteins ,Microbiology (medical) ,tight junctions ,beta-Defensins ,Antimicrobial peptides ,Immunology ,Microbiology ,03 medical and health sciences ,antimicrobial peptides ,0302 clinical medicine ,Cellular and Infection Microbiology ,Intestinal mucosa ,Candida albicans ,medicine ,microbiota ,Humans ,Intestinal Mucosa ,Original Research ,Innate immune system ,Intestinal permeability ,biology ,Chemistry ,Beta-defensin 2 ,Candidiasis ,Candida albicans, microbiota, antimicrobial peptides, gut, tight junctions ,medicine.disease ,biology.organism_classification ,QR1-502 ,Corpus albicans ,030104 developmental biology ,Infectious Diseases ,030220 oncology & carcinogenesis ,gut ,Dysbiosis - Abstract
The intestinal mucosa is composed of a monolayer of epithelial cells, which is highly polarized and firmly united to each other thanks to the presence of proteins complexes, called Tight junctions (TJs). Alteration of the mucus layer and TJs causes an increase in intestinal permeability, which can lead to a microbial translocation and systemic disorders. Candida albicans, in addition to its role of commensal, is an opportunistic pathogen responsible for disseminated candidiasis, especially in immunocompromised subjects where the dysbiosis leads to damage of the intestinal mucosal barrier . In this work, we used a line of intestinal epithelial cells able to stably express the genes that encodes human beta defensin-2 (HBD-2) and -3 (HBD-3) to monitor the invasion of C. albicans in vitro. Defensins are a group of antimicrobial peptides (AMPs) found in different living organisms, and are involved in the first line of defense in the innate immune response against pathogens. The results obtained show that the presence of antimicrobial peptides improves the expression of TJs and increases the Trans Epithelial Electrical Resistence value. In addition, the invasive ability of C. albicans in transfected cells is significantly reduced, as well as the expression levels of genes involved in the apoptotic pathway. Through the study of interaction between antimicrobial peptides and microbiota we will be able in the future to better understand the mechanisms by which they exert the host defense function against intestinal pathogens.
- Published
- 2021
- Full Text
- View/download PDF
29. Lactobacillus brevis CD2: Fermentation Strategies and Extracellular Metabolites Characterization
- Author
-
Donatella Cimini, Maria Michela Corsaro, Alberto Alfano, Chiara Schiraldi, Alessandra Fusco, Giovanna Donnarumma, Filomena Perillo, Vittoria Savio, Alfano, A., Perillo, F., Fusco, A., Savio, V., Corsaro, M. M., Donnarumma, G., Schiraldi, C., and Cimini, D.
- Subjects
0301 basic medicine ,Salmonella typhimurium ,030106 microbiology ,Levilactobacillus brevis ,Chemical Fractionation ,Antimicrobial activity ,Fed-batch processe ,Probiotic ,Microbiology ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,Nutraceutical ,law ,Functional Food ,Exopolysaccharide ,Extracellular ,Humans ,Food science ,Lactic Acid ,Molecular Biology ,Pathogen ,biology ,Lactobacillus brevis ,Probiotics ,Polysaccharides, Bacterial ,Ultrafiltration membrane ,Hydrogen-Ion Concentration ,biology.organism_classification ,Lactic acid ,Culture Media ,Molecular Weight ,Oxygen ,Lactobacillus brevi ,030104 developmental biology ,chemistry ,Batch Cell Culture Techniques ,Dietary Supplements ,Fermentation ,Molecular Medicine ,Growth inhibition - Abstract
Functional foods and nutraceuticals frequently contain viable probiotic strains that, at certain titers, are considered to be responsible of beneficial effects on health. Recently, it was observed that secreted metabolites might play a key role in this respect, especially in immunomodulation. Exopolysaccharides produced by probiotics, for example, are used in the food, pharmaceutical, and biomedical fields, due to their unique properties. Lactobacillus brevis CD2 demonstrated the ability to inhibit oral pathogens causing mucositis and periodontal inflammation and to reduce Helycobacter pylori infections. Due to the lack of literature, for this strain, on the development of fermentation processes that can increase the titer of viable cells and associated metabolites to industrially attractive levels, different batch and fed-batch strategies were investigated in the present study. In particular, aeration was shown to improve the growth rate and the yields of lactic acid and biomass in batch cultures. The use of an exponential feeding profile in fed-batch experiments allowed to produce 9.3 ± 0.45 × 109CFU/mL in 42h of growth, corresponding to a 20-fold increase of viable cells compared with that obtained in aerated batch processes; moreover, also increased titers of exopolysaccharides and lactic acid (260 and 150%, respectively) were observed. A purification process based on ultrafiltration, charcoal treatment, and solvent precipitation was applied to partially purify secreted metabolites and separate them into two molecular weight fractions (above and below 10kDa). Both fractions inhibited growth of the known gut pathogen, Salmonella typhimurium, demonstrating that lactic acid plays a major role in pathogen growth inhibition, which is however further enhanced by the presence of Lact. brevis CD2 exopolysaccharides. Finally, the EPS produced from Lact. brevis CD2 was characterized by NMR for the first time up to date.
- Published
- 2020
30. The Intestinal Biofilm of Pseudomonas aeruginosa and Staphylococcus aureus Is Inhibited by Antimicrobial Peptides HBD-2 and HBD-3
- Author
-
Giovanna Donnarumma, Vittoria Savio, Alessandra Fusco, Debora Stelitano, Adone Baroni, Fusco, A., Savio, V., Stelitano, D., Baroni, A., and Donnarumma, G.
- Subjects
intestinal microbiota ,0301 basic medicine ,Staphylococcus aureus ,Technology ,QH301-705.5 ,medicine.drug_class ,QC1-999 ,030106 microbiology ,Antibiotics ,Antimicrobial peptides ,Endogeny ,Biology ,medicine.disease_cause ,digestive system ,biofilm ,Microbiology ,antimicrobial peptides ,03 medical and health sciences ,fluids and secretions ,medicine ,General Materials Science ,Biology (General) ,QD1-999 ,Instrumentation ,Fluid Flow and Transfer Processes ,Pseudomonas aeruginosa ,Physics ,Process Chemistry and Technology ,General Engineering ,Biofilm ,dysbiosis ,Transfection ,Engineering (General). Civil engineering (General) ,medicine.disease ,Dysbiosi ,Computer Science Applications ,Chemistry ,stomatognathic diseases ,030104 developmental biology ,TA1-2040 ,Antimicrobial peptide ,Dysbiosis - Abstract
Background: The intestinal microbiota is a very active microbial community interacting with the host in maintaining homeostasis, it acts in cooperation with intestinal epithelial cells, which protect the host from the external environment by producing a diverse arsenal of antimicrobial peptides (AMPs), including β-defensins-2 and 3 (HBD-2 and HBD-3), considered among the most studied in this category. However, there are some circumstances in which an alteration of this eubiotic state occurs, with the triggering of dysbiosis. In this condition, the microbiota loses its protective power, leading to the onset of opportunistic infections. In this scenario, the emergence of multi-drug resistant biofilms from Pseudomonas aeruginosa and Staphylococcus aureus is very frequent. Methods: We created a Caco-2 intestinal epithelial cell line stably transfected with the genes, encoding HBD-2 and HBD-3, in order to evaluate their ability to inhibit the intestinal biofilm formation of P. aeruginosa and S. aureus. Results: Both HBD-2 and HBD-3 showed anti-biofilm activity against P. aeruginosa and S. aureus. Conclusions: The exploitation of endogenous antimicrobial peptides as a new anti-biofilm therapy, in isolation or in combination with conventional antibiotics, can be an interesting prospect in the treatment of chronic and multi-drug resistant infections.
- Published
- 2021
31. Monitoring of Non-Maximum-Residue-Level Pesticides in Animal Feed: A Study from 2019 to 2023.
- Author
-
Giugliano R, Armenio V, Savio V, Vaccaro E, Ciccotelli V, and Vivaldi B
- Abstract
Pesticides play a critical role in modern agriculture by protecting crops and ensuring higher yields, but their widespread use raises concerns about human health and environmental impact. Regulatory agencies impose Maximum Residue Levels (MRLs) to ensure safety, and the European Food Safety Authority (EFSA) assesses pesticide risks. This study monitored pesticide residues in 169 feed samples from Piedmont (Italy) collected between 2019 and 2023. Using GC-MS/MS, residues were found in 92% of animal-based and 70% of cereal-based feedstuffs. The most common pesticides in cereal-based feeds were pyrimiphos-methyl, deltamethrin, cypermethrin, azoxystrobin, and tetramethrin, and the pesticide synergist piperonyl-butoxide demonstrated a significant increase in contaminated samples in 2023. The lower concentrations in 2021 were likely due to COVID-19 impacts on pesticide availability. In animal-based feeds, common pesticides included deltamethrin, cypermethrin, and the pesticide synergist piperonyl-butoxide. The results highlight the pervasive presence of low-dose pesticide mixtures in feed and food chains, which could impact health, although do not pose acute risks. The study emphasizes the need for ongoing pesticide monitoring and awareness of the long-term effects of chronic pesticide exposure on animal, human, and environmental health.
- Published
- 2024
- Full Text
- View/download PDF
32. Q-switched Nd:YAG laser protects human keratinocytes from oxidative stress and inflammation via AhR-Nrf2 pathway.
- Author
-
Fusco A, Savio V, Perfetto B, Donniacuo M, Shadrina E, Donnarumma G, and Baroni A
- Subjects
- Humans, NF-E2-Related Factor 2, Antioxidants, Keratinocytes radiation effects, Inflammation radiotherapy, Inflammation pathology, Oxidative Stress, Lasers, Solid-State therapeutic use
- Abstract
In recent years, some treatments for esthetic and pathologic skin conditions have increasingly been based on the use of non-ablative neodymium-doped yttrium aluminum garnet (Nd:YAG) laser due to its greater penetration ability than other types of lasers, few contraindications, minimal side effects, no damage for epidermidis and the rapid recovery of the treated patients. The skin is frequently exposed to many stressors such as radiation, toxic substances, metabolites, foods, mechanical insults, and allergen exposition that cause oxidative damage and have a decisive influence on the aging process. The imbalance between reactive oxygen species, reactive nitrogen species, and the malfunctioning of the antioxidant defense system promotes the establishment of an excessive inflammatory process, which can induce various diseases including cancer and neurodegenerative disorders. The present study investigated the cytoprotective function of Q-switched Nd:YAG laser against stress aging and cell injury in HaCaT cells. We evaluated the effect of the laser on antioxidant defenses, inflammation, metalloproteinases' expression, and the AhR-Nrf2 pathway. Q-switched Nd:YAG is able to upregulate the AhR pathway and the expression of IL-6 and TGF-β, which are involved in wound repair process, and to downregulate the expression of MMP-2 and 9, so preventing the collagen degradation. Q-switched Nd:YAG can stimulate the cellular antioxidant defenses by activating the AhR-Nrf2 system., (© 2023. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
33. Regulatory Ability of Lactiplantibacillus plantarum on Human Skin Health by Counteracting In Vitro Malassezia furfur Effects.
- Author
-
Fusco A, Perfetto B, Savio V, Chiaromonte A, Torelli G, Donnarumma G, and Baroni A
- Abstract
The skin serves as the first barrier against pathogen attacks, thanks to its multifunctional microbial community. Malassezia furfur is a commensal organism of normal cutaneous microflora but is also a cause of skin diseases. It acts on different cell pattern recognition receptors (TLRs, AhR, NLRP3 inflammasome) leading to cellular damage, barrier impairment, and inflammatory cytokines production. Lactobacillus spp. Is an endogenous inhabitant of healthy skin, and studies have proven its beneficial role in wound healing, skin inflammation, and protection against pathogen infections. The aim of our study is to demonstrate the ability of live Lactiplantibacillus plantarum to interfere with the harmful effects of the yeast on human keratinocytes (HaCat) in vitro. To enable this, the cells were treated with M. furfur , either alone or in the presence of L. plantarum . To study the inflammasome activation, cells require a stimulus triggering inflammation (LPS) before M. furfur infection, with or without L. plantarum. L. plantarum effectively counteracts all the harmful strategies of yeast, reducing the phospholipase activity, accelerating wound repair, restoring barrier integrity, reducing AhR and NLRP3 inflammasome activation, and, consequently, releasing inflammatory cytokines. Although lactobacilli have a long history of use in fermented foods, it can be speculated that they can also have health-promoting activities when topically applied.
- Published
- 2023
- Full Text
- View/download PDF
34. Oreoch-1: A Peptide from Oreochromis niloticus as a Potential Tool against Staphylococci.
- Author
-
Palma F, Chianese A, Panico E, Greco G, Fusco A, Savio V, Ruocco E, Monti A, Doti N, Zannella C, Donnarumma G, De Filippis A, and Galdiero M
- Abstract
Staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis , are important human pathogens associated with potentially life-threatening infections. Their great biofilm-producing ability and the development of resistance mechanisms often account for therapeutic failure. Hence, the scientific community has devoted intensive efforts to the development of antimicrobial compounds active against both planktonic and sessile bacterial populations. Contextually, antimicrobial peptides (AMPs) are natural peptides produced by the innate immunity of every organism, representing a potential new therapeutic solution against human microbial pathogens. Our work focused on the in vitro activity of Oreoch-1, an AMP from the gills of Nile tilapia ( Oreochromis niloticus ), against standard and clinical S. aureus and S. epidermidis strains. Firstly, the cytotoxicity profile of Oreoch-1 was determined in human colon carcinoma cells. Secondly, its antibacterial spectrum was explored against staphylococcal strains to set up the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). Our results highlighted an antibacterial activity in the range 6.25-25 μM, with a general bacteriostatic effect. Therefore, the biofilm-inhibitory property was assessed against S. aureus ATCC 25923 and S. epidermidis ATCC 35984, indicating a significant reduction in S. aureus biomass at sub-MIC concentrations. Overall, our study indicates Oreoch-1 as a promising new therapeutic weapon against staphylococcal infections.
- Published
- 2023
- Full Text
- View/download PDF
35. Evaluation of Different Activity of Lactobacillus spp. against Two Proteus mirabilis Isolated Clinical Strains in Different Anatomical Sites In Vitro: An Explorative Study to Improve the Therapeutic Approach.
- Author
-
Fusco A, Savio V, Chiaromonte A, Alfano A, D'Ambrosio S, Cimini D, and Donnarumma G
- Abstract
Urinary tract infections (UTIs) and catheter-associated UTIs (CAUTIs) are the principal hospital-acquired infections. Between these, bacterial prostatitis is believed to be the leading cause of recurrent UTIs in men under 50 years of age and is often unresponsive to antibiotic treatment. Proteus mirabilis is more commonly associated with UTIs in these abnormalities, especially in patients undergoing catheterization. Lactobacillus spp. are an important component of the human microbiota and occur in large quantities in foods. Probiotics are proposed as an alternative to antibiotic therapy in the treatment of urinary tract infections. In addition to their ability to produce antimicrobial metabolites, they have immunomodulatory activity and do not cause side effects. For this reason, the combination of probiotic microorganisms and conventional drugs was considered. The aim of this work was to select the most active Lactobacillus strains against two clinical isolates of P. mirabilis on bladder and prostatic epithelium, potentially exploitable to improve the clinical management of UTIs.
- Published
- 2023
- Full Text
- View/download PDF
36. Soy, Rice and Oat Drinks: Investigating Chemical and Biological Safety in Plant-Based Milk Alternatives.
- Author
-
Giugliano R, Musolino N, Ciccotelli V, Ferraris C, Savio V, Vivaldi B, Ercolini C, Bianchi DM, and Decastelli L
- Subjects
- Animals, Milk, Lactose, Avena, Oryza, Lactose Intolerance
- Abstract
During the last decades, plant-based milk has become very appreciated by consumers, becoming a staple ingredient, especially for alternative breakfasts. Milk contains lactose, which is a sugar hydrolysed by the lactase enzyme. Lactose intolerance and lactose malabsorption are very common food intolerances among individuals. However, a lot of consumers consider themselves as lactose intolerant on the basis of self-reported intolerance and start to avoid dairy products, ignoring that plant-based milk alternatives are not nutritionally comparable to animal milk, especially in terms of protein intake. The aim of this study is to grow folder knowledge of the security of plant-based drinks, helping competent authorities to issue a risk assessment and to apply national plans about consumer safety. Results show that proper sanitary practices, such as pasteurization, are necessary in plant-based milk alternatives as well as in dairy milk. Chemical analysis has highlighted that there are no pesticide risks for consumers.
- Published
- 2023
- Full Text
- View/download PDF
37. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.
- Author
-
Maguire S, Al-Emadi S, Alba P, Aguiar MC, Al Lawati T, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez KJ, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu TYT, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich DA, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel NJ, Pera M, Pisoni C, Pons-Estel G, Quiambao AL, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales RS, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner ML, Wise L, Worthing AB, Zell J, Zepa J, Machado PM, Yazdany J, Robinson P, and Conway R
- Subjects
- Pregnancy, Infant, Newborn, Female, Humans, COVID-19 Vaccines, COVID-19 Testing, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, Rheumatic Diseases drug therapy, Premature Birth
- Abstract
Objective: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy., Methods: Data regarding pregnant women entered into the COVID-19 Global Rheumatology Alliance registry from 24 March 2020-25 February 2022 were analysed. Obstetric outcomes were stratified by number of COVID-19 vaccine doses received prior to COVID-19 infection in pregnancy. Descriptive differences between groups were tested using the chi-squared or Fisher's exact test., Results: There were 73 pregnancies in 73 women with RMD and COVID-19. Overall, 24.7% (18) of pregnancies were ongoing, while of the 55 completed pregnancies, 90.9% (50) of pregnancies resulted in livebirths. At the time of COVID-19 diagnosis, 60.3% (n = 44) of women were unvaccinated, 4.1% (n = 3) had received one vaccine dose while 35.6% (n = 26) had two or more doses. Although 83.6% (n = 61) of women required no treatment for COVID-19, 20.5% (n = 15) required hospital admission. COVID-19 resulted in delivery in 6.8% (n = 3) of unvaccinated women and 3.8% (n = 1) of fully vaccinated women. There was a greater number of preterm births (PTB) in unvaccinated women compared with fully vaccinated 29.5% (n = 13) vs 18.2% (n = 2)., Conclusions: In this descriptive study, unvaccinated pregnant women with RMD and COVID-19 had a greater number of PTB compared with those fully vaccinated against COVID-19. Additionally, the need for COVID-19 pharmacological treatment was uncommon in pregnant women with RMD regardless of vaccination status. These results support active promotion of COVID-19 vaccination in women with RMD who are pregnant or planning a pregnancy., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2023
- Full Text
- View/download PDF
38. In Vitro Evaluation of the Most Active Probiotic Strains Able to Improve the Intestinal Barrier Functions and to Prevent Inflammatory Diseases of the Gastrointestinal System.
- Author
-
Fusco A, Savio V, Cimini D, D'Ambrosio S, Chiaromonte A, Schiraldi C, and Donnarumma G
- Abstract
Background : The integrity of the intestinal barrier is fundamental to gut health and homeostasis; its damage can increase intestinal permeability, with translocation of bacteria and/or endotoxins from gut, and the onset of various intestinal diseases. Lactobacillus spp. is one of the most common probiotics normally found in fermented foods and dairy products and is known for its anti-inflammatory and immunomodulatory properties and for its ability to protect and enhance the intestinal barrier functions. The aim of this work was to evaluate the ability of different strains of Lactobacillus spp. to improve in vitro the integrity of the intestinal barrier, to exert anti-inflammatory and immunomodulatory activity and to prevent Salmonella Typhimurium and enteroinvasive Escherichia coli (EIEC) infections. Methods : We analyzed the cellular expression of tight junctions, antimicrobial peptide HBD-2, pro-inflammatory cytokines and the inhibition of pathogens adhesion and invasion in a model of co-cultured epithelial cells treated with Lactobacillus spp. Results : L. brevis, L. reuteri and L. rhamnosus proved to be more effective in protecting the intestinal epithelium. Conclusions: These in vitro studies can help select strains particularly active in their intended use to obtain consortia formulations that can have as much maximum yield as possible in terms of patient benefit.
- Published
- 2023
- Full Text
- View/download PDF
39. An Unconventional Oral Candidiasis in an Immunocompetent Patient.
- Author
-
Fusco A, Contaldo M, Savio V, Baroni A, Ferraro GA, Di Stasio D, Lucchese A, Chiaromonte A, Donnarumma G, and Serpico R
- Abstract
Oral candidiasis (OC) is an opportunistic fungal infection of the oral mucosae, sustained by Candida albicans or other non-albican Candida species (NAC), usually eradicated by conventional antifungals of the classes of azoles, polyenes, or derivative from echinocandins. OC usually occurs under predisposing local or systemic factors. C. lusitaniae is an opportunistic strain that is rarely responsible for human infection and occurs mainly in severe immunocompromised states. The present work reported an unconventional case of OC in an otherwise healthy immunocompetent woman sustained by C. lusitaniae and a multi-resistant strain of C. albicans .
- Published
- 2023
- Full Text
- View/download PDF
40. Antimicrobial peptide human β-defensin-2 improves in vitro cellular viability and reduces pro-inflammatory effects induced by enteroinvasive Escherichia coli in Caco-2 cells by inhibiting invasion and virulence factors' expression.
- Author
-
Fusco A, Savio V, Perfetto B, Mattina R, and Donnarumma G
- Subjects
- Child, Humans, Antimicrobial Peptides, Caco-2 Cells, Diarrhea microbiology, Virulence Factors genetics, beta-Defensins pharmacology, Escherichia coli genetics
- Abstract
Escherichia coli is one of the commensal species most represented in the intestinal microbiota. However, there are some strains that can acquire new virulence factors that enable them to adapt to new intestinal niches. These include enteroinvasive E. coli (EIEC) that is responsible for the bacillary dysentery that causes severe diarrheal symptoms in both children and adults. Due to the increasing onset of antibiotic resistance phenomena, scientific research is focused on the study of other therapeutic approaches for the treatment of bacterial infections. A promising alternative could be represented by antimicrobial peptides (AMPs), that have received widespread attention due to their broad antimicrobial spectrum and low incidence of bacterial resistance. AMPs modulate the immune defenses of the host and regulate the composition of microbiota and the renewal of the intestinal epithelium. With the aim to investigate an alternative therapeutic approach, especially in the case of antibiotic resistance, in this work we created a line of intestinal epithelial cells able to express high concentrations of AMP human β-defensin-2 (HBD-2) in order to test its ability to interfere with the pathogenicity mechanisms of EIEC. The results showed that HBD-2 is able to significantly reduce the expression of the proinflammatory cytokines by intestinal epithelial cells, the invasiveness ability of EIEC and the expression of invasion-associated genes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Fusco, Savio, Perfetto, Mattina and Donnarumma.)
- Published
- 2022
- Full Text
- View/download PDF
41. Decreased expression of Malassezia furfur virulence factors after Q-switched Nd:YAG laser irradiation.
- Author
-
Fusco A, Savio V, Cammarota M, Donnarumma G, and Baroni A
- Abstract
Malassezia spp. are lipophilic yeasts implicated in the pathogenesis of chronic skin diseases. Repeated therapies are often necessary due to the recurrence of this type of disease. Recently, laser and light-based devices used for the treatment of some skin diseases have shown good efficacy, few contraindications, and minimal side effects. The neodymium-doped yttrium aluminium garnet (Q-switched Nd:YAG) laser is one of the most commonly used lasers in dermatology. The aim of this study was to evaluate the effect of the Q-switched Nd:YAG laser (Medlite C6 laser, Conbio, USA) on the pathogenic mechanisms of M. furfur during skin infections. Following laser exposure, the ability of M. furfur to retain phospholipase activity, upregulate the aryl receptor and its associated pathway, and stimulate the immune response were tested. The Q-switched Nd:YAG laser was shown to attenuate the virulence of M. furfur. The Q-switched Nd:YAG laser should be considered as a valid therapeutic alternative for the treatment of Malassezia-associated infections.
- Published
- 2021
- Full Text
- View/download PDF
42. Antimicrobial Peptides Human Beta-Defensin-2 and -3 Protect the Gut During Candida albicans Infections Enhancing the Intestinal Barrier Integrity: In Vitro Study.
- Author
-
Fusco A, Savio V, Donniacuo M, Perfetto B, and Donnarumma G
- Subjects
- Candida albicans, Humans, Intestinal Mucosa, Pore Forming Cytotoxic Proteins, Candidiasis, beta-Defensins
- Abstract
The intestinal mucosa is composed of a monolayer of epithelial cells, which is highly polarized and firmly united to each other thanks to the presence of proteins complexes, called Tight junctions (TJs). Alteration of the mucus layer and TJs causes an increase in intestinal permeability, which can lead to a microbial translocation and systemic disorders. Candida albicans , in addition to its role of commensal, is an opportunistic pathogen responsible for disseminated candidiasis, especially in immunocompromised subjects where the dysbiosis leads to damage of the intestinal mucosal barrier . In this work, we used a line of intestinal epithelial cells able to stably express the genes that encodes human beta defensin-2 (HBD-2) and -3 (HBD-3) to monitor the invasion of C. albicans in vitro. Defensins are a group of antimicrobial peptides (AMPs) found in different living organisms, and are involved in the first line of defense in the innate immune response against pathogens. The results obtained show that the presence of antimicrobial peptides improves the expression of TJs and increases the Trans Epithelial Electrical Resistence value. In addition, the invasive ability of C. albicans in transfected cells is significantly reduced, as well as the expression levels of genes involved in the apoptotic pathway. Through the study of interaction between antimicrobial peptides and microbiota we will be able in the future to better understand the mechanisms by which they exert the host defense function against intestinal pathogens., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Fusco, Savio, Donniacuo, Perfetto and Donnarumma.)
- Published
- 2021
- Full Text
- View/download PDF
43. Lactobacillus brevis CD2: Fermentation Strategies and Extracellular Metabolites Characterization.
- Author
-
Alfano A, Perillo F, Fusco A, Savio V, Corsaro MM, Donnarumma G, Schiraldi C, and Cimini D
- Subjects
- Batch Cell Culture Techniques methods, Chemical Fractionation methods, Culture Media chemistry, Dietary Supplements, Fermentation, Functional Food, Humans, Hydrogen-Ion Concentration, Levilactobacillus brevis drug effects, Molecular Weight, Oxygen pharmacology, Polysaccharides, Bacterial isolation & purification, Polysaccharides, Bacterial pharmacology, Salmonella typhimurium drug effects, Salmonella typhimurium growth & development, Culture Media pharmacology, Lactic Acid biosynthesis, Levilactobacillus brevis metabolism, Polysaccharides, Bacterial biosynthesis, Probiotics analysis
- Abstract
Functional foods and nutraceuticals frequently contain viable probiotic strains that, at certain titers, are considered to be responsible of beneficial effects on health. Recently, it was observed that secreted metabolites might play a key role in this respect, especially in immunomodulation. Exopolysaccharides produced by probiotics, for example, are used in the food, pharmaceutical, and biomedical fields, due to their unique properties. Lactobacillus brevis CD2 demonstrated the ability to inhibit oral pathogens causing mucositis and periodontal inflammation and to reduce Helycobacter pylori infections. Due to the lack of literature, for this strain, on the development of fermentation processes that can increase the titer of viable cells and associated metabolites to industrially attractive levels, different batch and fed-batch strategies were investigated in the present study. In particular, aeration was shown to improve the growth rate and the yields of lactic acid and biomass in batch cultures. The use of an exponential feeding profile in fed-batch experiments allowed to produce 9.3 ± 0.45 × 10
9 CFU/mL in 42 h of growth, corresponding to a 20-fold increase of viable cells compared with that obtained in aerated batch processes; moreover, also increased titers of exopolysaccharides and lactic acid (260 and 150%, respectively) were observed. A purification process based on ultrafiltration, charcoal treatment, and solvent precipitation was applied to partially purify secreted metabolites and separate them into two molecular weight fractions (above and below 10 kDa). Both fractions inhibited growth of the known gut pathogen, Salmonella typhimurium, demonstrating that lactic acid plays a major role in pathogen growth inhibition, which is however further enhanced by the presence of Lact. brevis CD2 exopolysaccharides. Finally, the EPS produced from Lact. brevis CD2 was characterized by NMR for the first time up to date.- Published
- 2020
- Full Text
- View/download PDF
44. Induction of Different Apoptosis Pathways by Two Proteus mirabilis Clinical Isolates Strains in Prostatic Epithelial Cells.
- Author
-
Fusco A, Savio V, De Filippis A, Tufano A, and Donnarumma G
- Abstract
Bacterial prostatitis is believed to be the leading cause of recurrent urinary tract infections (UTIs) in men under 50 years of age and occurs both as an acute febrile disease responsive to antibiotics and as a chronic infection that is often unresponsive to antibiotic treatment. Proteus mirabilis is more commonly associated with UTIs in these abnormalities, especially in patients undergoing catheterisation. This pathogen is able to colonise the host's tissues and to cause disease thanks to the production of many virulence factors such as fimbriae, flagella, immune avoidance, host-damaging factors, and the ability to form crystalline biofilms. In addition, Proteus lipid A may exhibit apoptotic activity and induce desquamation of epithelial cells. The aim of this work was to evaluate the ability of two clinically isolated strains of P. mirabilis that are phenotypically different, named PM1 of PM2, respectively, to induce apoptosis in human prostatic adenocarcinoma PC-3. Our results demonstrate that PM1 and PM2 are able to activate two different apoptotic pathways, and this different behaviour is confirmed by the expression level of the ZapA gene, molecular fingerprinting and different spectrum of antibiotic resistance. The identification and knowledge of relations between the microorganism and host may provide the basis for new solutions to clinical problems with regard to diagnosis and therapy.
- Published
- 2018
- Full Text
- View/download PDF
45. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus )-Pan-American League of Associations of Rheumatology (PANLAR).
- Author
-
Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, Criniti JM, Vásquez G, Massardo L, Duarte M, Barile-Fabris LA, García MA, Amigo MC, Espada G, Catoggio LJ, Sato EI, Levy RA, Acevedo Vásquez EM, Chacón-Díaz R, Galarza-Maldonado CM, Iglesias Gamarra AJ, Molina JF, Neira O, Silva CA, Vargas Peña A, Gómez-Puerta JA, Scolnik M, Pons-Estel GJ, Ugolini-Lopes MR, Savio V, Drenkard C, Alvarellos AJ, Ugarte-Gil MF, Babini A, Cavalcanti A, Cardoso Linhares FA, Haye Salinas MJ, Fuentes-Silva YJ, Montandon de Oliveira E Silva AC, Eraso Garnica RM, Herrera Uribe S, Gómez-Martín D, Robaina Sevrini R, Quintana RM, Gordon S, Fragoso-Loyo H, Rosario V, Saurit V, Appenzeller S, Dos Reis Neto ET, Cieza J, González Naranjo LA, González Bello YC, Collado MV, Sarano J, Retamozo S, Sattler ME, Gamboa-Cárdenas RV, Cairoli E, Conti SM, Amezcua-Guerra LM, Silveira LH, Borba EF, Pera MA, Alba Moreyra PB, Arturi V, Berbotto GA, Gerling C, Gobbi CA, Gervasoni VL, Scherbarth HR, Brenol JCT, Cavalcanti F, Costallat LTL, Da Silva NA, Monticielo OA, Seguro LPC, Xavier RM, Llanos C, Montúfar Guardado RA, Garcia de la Torre I, Pineda C, Portela Hernández M, Danza A, Guibert-Toledano M, Reyes GL, Acosta Colman MI, Aquino AM, Mora-Trujillo CS, Muñoz-Louis R, García Valladares I, Orozco MC, Burgos PI, Betancur GV, and Alarcón GS
- Subjects
- Antiphospholipid Syndrome etiology, Heart Diseases drug therapy, Heart Diseases etiology, Hematologic Diseases etiology, Humans, Kidney Diseases etiology, Latin America, Lung Diseases drug therapy, Lung Diseases etiology, Lupus Erythematosus, Systemic complications, Lupus Nephritis drug therapy, Lupus Nephritis etiology, Mental Disorders drug therapy, Mental Disorders etiology, Musculoskeletal Diseases drug therapy, Musculoskeletal Diseases etiology, Skin Diseases drug therapy, Skin Diseases etiology, Standard of Care, Antiphospholipid Syndrome drug therapy, Hematologic Diseases drug therapy, Kidney Diseases drug therapy, Lupus Erythematosus, Systemic drug therapy
- Abstract
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings., Competing Interests: Competing interests: LBF, BAPE and OAM have been speakers for GlaxoSmithKline (GSK). JCTB has received research grants from GSK. RMX, ON and JFM have received support grants for meetings from GSK. JAGP has been a lecturer for Roche. ERS has received research grants and has been a lecturer for Roche. JFM has been a clinical researcher for Anthera. MHC has received research grants from Roche and is an advisor for Eli Lilly., (© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2018
- Full Text
- View/download PDF
46. Biofilm Formation and Immunomodulatory Activity of Proteus mirabilis Clinically Isolated Strains.
- Author
-
Fusco A, Coretti L, Savio V, Buommino E, Lembo F, and Donnarumma G
- Subjects
- Gene Expression Regulation, Bacterial, Genes, Bacterial, Host-Pathogen Interactions immunology, Humans, Phenotype, Proteus mirabilis classification, Proteus mirabilis isolation & purification, Urinary Tract Infections immunology, Urinary Tract Infections microbiology, Virulence Factors, Biofilms growth & development, Immunomodulation, Proteus Infections immunology, Proteus Infections microbiology, Proteus mirabilis physiology
- Abstract
Urinary tract infections (UTIs) and catheter-associated UTIs (CAUTIs) are the principal hospital-acquired infections. Proteus mirabilis is characterized by several virulence factors able to promote adhesion and biofilm formation and ameliorate the colonization of urinary tract and the formation of crystalline biofilms on the abiotic surface of the urinary catheters. Since, to date, the role of P. mirabilis in the etiopathogenesis of different types of urinary tract infections is not well established, in this study we sought to characterize two different clinically isolated strains of P. mirabilis (PM1 and PM2) with distinctive phenotypes and analyzed various virulence factors possibly implicated in the ability to induce UTIs and CAUTIs. In particular, we analyzed motility, biofilm formation both on abiotic and biotic surfaces of PM1 and PM2 and paralleled these parameters with the ability to induce an inflammatory response in an epithelial cell model. Results showed that PM1 displayed major motility and a capacity to form biofilm and was associated with an anti-inflammatory response of host cells. Conversely, PM2 exhibited lack motility and a had slower organization in biofilm but promoted an increase of proinflammatory cytokine expression in infected epithelial cells. Our study provides data useful to start uncovering the pathologic basis of P. mirabilis -associated urinary infections. The evidence of different virulence factors expressed by PM1 and PM2 highlights the possibility to use precise and personalized therapies targeting specific virulence pathways.
- Published
- 2017
- Full Text
- View/download PDF
47. Beta-Defensin-2 and Beta-Defensin-3 Reduce Intestinal Damage Caused by Salmonella typhimurium Modulating the Expression of Cytokines and Enhancing the Probiotic Activity of Enterococcus faecium .
- Author
-
Fusco A, Savio V, Cammarota M, Alfano A, Schiraldi C, and Donnarumma G
- Subjects
- Caco-2 Cells, Cell Culture Techniques, Cytokines genetics, Gene Expression Regulation, Humans, Immunomodulation, Microbiota, Probiotics, beta-Defensins genetics, Cytokines metabolism, Enterococcus faecium physiology, Intestinal Mucosa cytology, Salmonella Infections immunology, Salmonella typhimurium physiology, beta-Defensins metabolism
- Abstract
The intestinal microbiota is a major factor in human health and disease. This microbial community includes autochthonous (permanent inhabitants) and allochthonous (transient inhabitants) microorganisms that contribute to maintaining the integrity of the intestinal wall, modulating responses to pathogenic noxae and representing a key factor in the maturation of the immune system. If this healthy microbiota is disrupted by antibiotics, chemotherapy, or a change in diet, intestinal colonization by pathogenic bacteria or viruses may occur, leading to disease. To manage substantial microbial exposure, epithelial surfaces of the intestinal tract produce a diverse arsenal of antimicrobial peptides (AMPs), including, of considerable importance, the β -defensins, which directly kill or inhibit the growth of microorganisms. Based on the literature data, the purpose of this work was to create a line of intestinal epithelial cells able to stably express gene encoding human β -defensin-2 (hBD-2) and human β -defensin-3 (hBD-3), in order to test their role in S. typhimurium infections and their interaction with the bacteria of the gut microbiota.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.